ZHEJIANG ZHENYUAN SHARE CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.85 CNY | +6.66% |
|
+9.94% | -27.92% |
| 04-29 | Zhejiang Zhenyuan Share Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-15 | Zhejiang Zhenyuan Share Co.,Ltd. Approves Cash Dividend for the Year 2023 | CI |
| Sales 2022 | 4.15B 572M 45.63B | Sales 2023 | 4.11B 567M 45.2B | Capitalization | 3.64B 502M 40.05B |
|---|---|---|---|---|---|
| Net income 2022 | 77M 10.63M 848M | Net income 2023 | 81M 11.18M 892M | EV / Sales 2022 | 0.55 x |
| Net cash position 2022 | 372M 51.4M 4.1B | Net cash position 2023 | 373M 51.49M 4.11B | EV / Sales 2023 | 0.8 x |
| P/E ratio 2022 |
34.5
x | P/E ratio 2023 |
45.4
x | Employees | 1,974 |
| Yield 2022 |
0.76% | Yield 2023 |
0.55% | Free-Float | 68.66% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.66% | ||
| 1 week | +9.94% | ||
| Current month | +1.29% | ||
| 1 month | +1.29% | ||
| 3 months | -5.19% | ||
| 6 months | -9.56% | ||
| Current year | -27.92% |
1 week
7.13
7.98
1 month
6.868.12
Current year
6.0811.98
1 year
6.0811.98
3 years
6.0811.98
5 years
5.8311.98
10 years
5.4728.16
| Managers | Title | Age | Since |
|---|---|---|---|
Yun Wei Chen
CEO | Chief Executive Officer | 55 | 19/12/19 |
Ming Hua Jin
DFI | Director of Finance/CFO | 63 | 14/09/17 |
Jun Chai
BRD | Director/Board Member | 44 | 14/09/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yu Long He
BRD | Director/Board Member | 61 | - |
Yang Li
BRD | Director/Board Member | 47 | - |
Jian Chang Ruan
BRD | Director/Board Member | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 7.85 | +6.66% | 19,227,570 |
| 26/04/24 | 7.36 | +1.10% | 6,201,002 |
| 25/04/24 | 7.28 | +0.41% | 5,853,202 |
| 24/04/24 | 7.25 | +1.12% | 4,699,210 |
| 23/04/24 | 7.17 | +0.42% | 4,544,712 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
ZHEJIANG ZHENYUAN SHARE CO., LTD. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company's primary business includes the pharmaceutical business, pharmaceutical industry, pharmaceutical logistics and health services business. The Company's main products include proprietary Chinese medicines, Chinese herbal medicines, Chinese herbal pieces, chemical medicine, chemical raw materials, biochemical drugs, narcotic drugs, psychotropic drugs, medical devices and chemical reagents. The Company mainly conducts its business in the domestic market.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -27.92% | 362M | |
| +15.79% | 70.45B | |
| +2.09% | 25.03B | |
| -2.98% | 8.05B | |
| +7.95% | 8.29B | |
| -20.48% | 7.97B | |
| +15.26% | 4.25B | |
| -1.24% | 4.04B | |
| -3.02% | 3.86B | |
| +21.10% | 3.61B |
- Stock Market
- Equities
- 000705 Stock
